Nattokinase

Nattokinase is a fibrinolytic enzyme extracted from natto — a traditional Japanese food made from soybeans fermented with Bacillus subtilis natto. Discovered in 1987 by Dr. Hiroyuki Sumi, it has the unique ability to dissolve fibrin, the main component of blood clots. It acts similarly to plasmin (endogenous fibrinolytic enzyme) and can also activate plasminogen — plasmin's precursor. Unlike pharmacological anticoagulants, it acts directly on dissolving already formed clots, not just prevention.

• Fibrinolytic action — dissolves clots and reduces blood viscosity
• Blood pressure reduction
• Cardiovascular health support
• May improve peripheral circulation
• May reduce risk of deep vein thrombosis
• Anti-inflammatory effect
• Vascular health support for sedentary people or long travelers

• •People with family history of cardiovascular disease
• •Individuals with mild hypertension
• •People who travel frequently and sit for long periods
• •Those seeking circulation and vascular health support
• •People with post-COVID syndrome and coagulation complaints
• •Sedentary individuals with cardiovascular risk

100mg to 200mg (2,000–4,000 FU — Fibrinolytic Units) per day, fasted or away from meals for maximum absorption. Doses split into 2 takes. Activity is measured in FU — check on the label.

Nattokinase is a niche supplement with specific application in cardiovascular and vascular health. It is not a sports performance supplement. Check the activity in FU (Fibrinolytic Units) on the label — the amount in mg is not sufficient without declared enzymatic activity. WARNING: Contraindicated in people using anticoagulants (warfarin, heparin, new oral anticoagulants) — real risk of bleeding. Consult a doctor before use if there is a history of coagulopathies or use of antiplatelet agents.

Nattokinase has growing evidence for cardiovascular health. Studies show reduction of systolic and diastolic blood pressure, improved blood viscosity and reduction of coagulation markers. A randomized controlled study showed significant blood pressure reduction in 8 weeks of use. In vitro and in vivo research demonstrates fibrinolytic activity superior to streptokinase in some models. Post-COVID studies show potential for dissolving microclots associated with post-COVID syndrome.

Generally well tolerated in healthy people without anticoagulants. Risk of bleeding in combination with anticoagulants or antiplatelets. May cause mild gastrointestinal discomfort. Avoid before surgeries. People with hemophilia or other coagulation disorders should avoid.